慢性乾癬の世界市場レポート 2025年

慢性乾癬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.1％で293億3,000万米ドルに成長します。予測期間中に予想される成長は、慢性乾癬（CPP）の世界の有病率の上昇または低下、自己免疫疾患の増加、ヘルスケア予算の増加、高齢化、効果的な治療に対する需要の高まりなどの要因に起因しています。この期間に予想される主な動向には、生物学的治療の発展、経口低分子阻害剤の開発、デジタルヘルス技術の統合、個別化医療の台頭、バイオシミラーの導入などがあります。

免疫系機能障害の罹患率の上昇は、慢性乾癬市場の成長を促進すると予想されます。免疫系機能不全は、免疫系が適切に機能しなくなることで発生し、感染症、自己免疫疾患、がんのリスクが高まる。この増加の要因としては、遺伝的素因、環境的誘因、栄養不良、慢性ストレス、自己免疫疾患やHIVなどの感染症の蔓延が挙げられます。慢性乾癬治療は、免疫系の機能不全を管理するために不可欠です。免疫系が誤って皮膚細胞の過剰生産を引き起こし、炎症やプラーク形成につながるからです。例えば、2022年12月、米国の非営利団体であるNational Psoriasis Foundationは、800万人以上の米国人が乾癬に罹患しており、世界全体では1億2,500万人が罹患しており、世界人口の2～3％に相当すると報告しています。その結果、免疫系機能不全の症例が増加しており、慢性乾癬市場の拡大に拍車をかけています。

慢性乾癬市場の主要企業は、慢性乾癬の治療を進展させるため、IL-17AやIL-17F阻害剤などの革新的な治療法の開発に注力しています。これらの阻害剤は、免疫反応に関与する炎症性サイトカインであるインターロイキン-17Aおよびインターロイキン-17Fを阻害する標的生物学的治療薬であり、慢性乾癬のような自己免疫疾患における炎症を抑えるのに役立ちます。例えば、2023年10月、ベルギーに本拠を置くバイオ医薬品会社UCB S.A.は、全身療法または光線療法の候補である中等度から重度の尋常性乾癬の成人患者を対象に、BIMZELX（bimekizumab-bkzx）が米国食品医薬品局（FDA）より承認されたと発表しました。ビメキズマブは、炎症に関与する2つの重要なサイトカインであるインターロイキン17A（IL-17A）とインターロイキン17F（IL-17F）を標的とし、これを阻害するように特別にデザインされた初めての乾癬治療薬です。この承認は、中等度から重度の尋常性乾癬患者1,480人を対象に安全性と有効性を評価した3つの第3相多施設共同試験（BE READY、BE VIVID、BE SURE）のデータに基づいています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界慢性乾癬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の慢性乾癬市場：成長率分析
• 世界の慢性乾癬市場の実績：規模と成長, 2019-2024
• 世界の慢性乾癬市場の予測：規模と成長, 2024-2029, 2034F
• 世界慢性乾癬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性乾癬市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生物学的製剤
• 低分子医薬品
• 世界の慢性乾癬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• オーラル
• トピック
• 世界の慢性乾癬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の慢性乾癬市場、生物製剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍壊死因子（TNF）阻害剤
• インターロイキン阻害剤（IL-12、IL-23、IL-17、IL-22）
• T細胞阻害剤
• その他
• 世界の慢性乾癬市場低分子医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホスホジエステラーゼ4（PDE4）阻害剤
• ヤヌスキナーゼ（JAK）阻害剤
• レチノイド
• その他

第7章 地域別・国別分析

• 世界の慢性乾癬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の慢性乾癬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性乾癬市場：競合情勢
• 慢性乾癬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim
• Biogen Inc.
• UCB S.A.
• Dr. Reddy's Laboratories
• Innovent Biologics Inc.
• Dong-A ST Co. Ltd.
• Alumis GmbH Co KG
• Zai Lab Limited
• GC Cell Corporation
• Affibody AB
• Nimbus Therapeutics
• Bio-Thera Solutions

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性乾癬市場2029：新たな機会を提供する国
• 慢性乾癬市場2029：新たな機会を提供するセグメント
• 慢性乾癬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic plaque psoriasis is a long-lasting, inflammatory skin condition marked by the development of well-defined, raised, red patches covered with silvery-white scales. These plaques commonly appear on areas such as the scalp, elbows, knees, and lower back, though they can form anywhere on the body. It is an autoimmune disorder where the immune system accelerates the turnover of skin cells, causing them to accumulate on the surface.

The primary drug classes used for treating chronic plaque psoriasis include biologics and small-molecule drugs. Biologics are advanced medications derived from living organisms that specifically target components of the immune system to treat various conditions. These drugs are available in injectable, oral, and topical forms and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The chronic plaque psoriasis market research report is one of a series of new reports from The Business Research Company that provides chronic plaque psoriasis market statistics, including chronic plaque psoriasis industry global market size, regional shares, competitors with a chronic plaque psoriasis market share, detailed chronic plaque psoriasis market segments, market trends and opportunities, and any further data you may need to thrive in the chronic plaque psoriasis industry. This chronic plaque psoriasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic plaque psoriasis market size has grown strongly in recent years. It will grow from $20.79 billion in 2024 to $22.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of psoriasis, a rise in co-morbidities, favorable reimbursement policies, higher consumption of alcohol and smoking, and the growing adoption of telemedicine.

The chronic plaque psoriasis market size is expected to see strong growth in the next few years. It will grow to $29.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth anticipated during the forecast period can be attributed to factors such as the rising or declining global prevalence of chronic plaque psoriasis (CPP), an increase in autoimmune diseases, growth in healthcare budgets, an aging population, and the growing demand for effective treatments. Key trends expected during this period include advancements in biologic treatments, the development of oral small molecule inhibitors, the integration of digital health technologies, the rise of personalized medicine, and the introduction of biosimilars.

The rising incidence of immune system dysfunction is expected to drive growth in the chronic plaque psoriasis market. Immune system dysfunction occurs when the immune system fails to function properly, resulting in a higher risk of infections, autoimmune diseases, and cancer. Contributing factors to this increase include genetic predispositions, environmental triggers, malnutrition, chronic stress, and the growing prevalence of autoimmune diseases and infections such as HIV. Chronic plaque psoriasis treatment is essential to manage immune system dysfunction, as the immune system erroneously causes an overproduction of skin cells, leading to inflammation and plaque formation. For example, in December 2022, the National Psoriasis Foundation, a US-based nonprofit organization, reported that more than 8 million Americans are affected by psoriasis, while globally, the condition impacts 125 million people, representing 2 to 3% of the world's population. As a result, the growing cases of immune system dysfunction are fueling the expansion of the chronic plaque psoriasis market.

Leading companies in the chronic plaque psoriasis market are concentrating on developing innovative treatments, such as IL-17A and IL-17F inhibitors, to make progress in treating chronic plaque psoriasis. These inhibitors are targeted biologic therapies that block the pro-inflammatory cytokines interleukin-17A and interleukin-17F, which play a role in the immune response, helping to reduce inflammation in autoimmune conditions such as chronic plaque psoriasis. For example, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Bimekizumab is the first psoriasis treatment specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two crucial cytokines involved in inflammation. Its approval was based on data from three Phase 3 multicenter trials-BE READY, BE VIVID, and BE SURE-which evaluated its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

In October 2024, Organon, a US-based healthcare company, acquired Dermavant Sciences Ltd. for an undisclosed sum. This acquisition strengthens Organon's dermatology portfolio by adding VTAMA (tapinarof) Cream, 1%, an innovative dermatologic treatment. VTAMA Cream is a novel, nonbiologic, non-steroidal topical therapy that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of mild, moderate, and severe plaque psoriasis in adults. Dermavant Sciences Ltd. is a US-based company dedicated to developing and commercializing groundbreaking therapies in the field of immunodermatology.

Major players in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy's Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., and Arcutis Biotherapeutics.

North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic plaque psoriasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic plaque psoriasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic plaque psoriasis market consists of revenues earned by entities by providing services such as medication delivery services, customized treatment plans, and genetic and biomarker testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic plaque psoriasis market also includes sales of vitamin D analogues, combination topicals, phosphodiesterase-4 inhibitors, and janus kinase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Plaque Psoriasis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic plaque psoriasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic plaque psoriasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic plaque psoriasis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Biologics; Small Molecule Drugs
• 2) By Route Of Administration: Injectable; Oral; Topical
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• Subsegments:
• 1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors; Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22); T-Cell Inhibitors; Others
• 2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors; Janus Kinase (JAK) Inhibitors; Retinoids; Others
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Plaque Psoriasis Market Characteristics

3. Chronic Plaque Psoriasis Market Trends And Strategies

4. Chronic Plaque Psoriasis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Plaque Psoriasis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Plaque Psoriasis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Plaque Psoriasis Market Growth Rate Analysis
• 5.4. Global Chronic Plaque Psoriasis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Plaque Psoriasis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Plaque Psoriasis Total Addressable Market (TAM)

6. Chronic Plaque Psoriasis Market Segmentation

• 6.1. Global Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Small Molecule Drugs
• 6.2. Global Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• Topical
• 6.3. Global Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.4. Global Chronic Plaque Psoriasis Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Necrosis Factor (TNF) Inhibitors
• Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22)
• T-Cell Inhibitors
• Others
• 6.5. Global Chronic Plaque Psoriasis Market, Sub-Segmentation Of Small Molecule Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phosphodiesterase 4 (PDE4) Inhibitors
• Janus Kinase (JAK) Inhibitors
• Retinoids
• Others

7. Chronic Plaque Psoriasis Market Regional And Country Analysis

• 7.1. Global Chronic Plaque Psoriasis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Plaque Psoriasis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Plaque Psoriasis Market

• 8.1. Asia-Pacific Chronic Plaque Psoriasis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Plaque Psoriasis Market

• 9.1. China Chronic Plaque Psoriasis Market Overview
• 9.2. China Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Plaque Psoriasis Market

• 10.1. India Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Plaque Psoriasis Market

• 11.1. Japan Chronic Plaque Psoriasis Market Overview
• 11.2. Japan Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Plaque Psoriasis Market

• 12.1. Australia Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Plaque Psoriasis Market

• 13.1. Indonesia Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Plaque Psoriasis Market

• 14.1. South Korea Chronic Plaque Psoriasis Market Overview
• 14.2. South Korea Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Plaque Psoriasis Market

• 15.1. Western Europe Chronic Plaque Psoriasis Market Overview
• 15.2. Western Europe Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Plaque Psoriasis Market

• 16.1. UK Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Plaque Psoriasis Market

• 17.1. Germany Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Plaque Psoriasis Market

• 18.1. France Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Plaque Psoriasis Market

• 19.1. Italy Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Plaque Psoriasis Market

• 20.1. Spain Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Plaque Psoriasis Market

• 21.1. Eastern Europe Chronic Plaque Psoriasis Market Overview
• 21.2. Eastern Europe Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Plaque Psoriasis Market

• 22.1. Russia Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Plaque Psoriasis Market

• 23.1. North America Chronic Plaque Psoriasis Market Overview
• 23.2. North America Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Plaque Psoriasis Market

• 24.1. USA Chronic Plaque Psoriasis Market Overview
• 24.2. USA Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Plaque Psoriasis Market

• 25.1. Canada Chronic Plaque Psoriasis Market Overview
• 25.2. Canada Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Plaque Psoriasis Market

• 26.1. South America Chronic Plaque Psoriasis Market Overview
• 26.2. South America Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Plaque Psoriasis Market

• 27.1. Brazil Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Plaque Psoriasis Market

• 28.1. Middle East Chronic Plaque Psoriasis Market Overview
• 28.2. Middle East Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Plaque Psoriasis Market

• 29.1. Africa Chronic Plaque Psoriasis Market Overview
• 29.2. Africa Chronic Plaque Psoriasis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Plaque Psoriasis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Plaque Psoriasis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Plaque Psoriasis Market Competitive Landscape And Company Profiles

• 30.1. Chronic Plaque Psoriasis Market Competitive Landscape
• 30.2. Chronic Plaque Psoriasis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Plaque Psoriasis Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Boehringer Ingelheim
• 31.5. Biogen Inc.
• 31.6. UCB S.A.
• 31.7. Dr. Reddy's Laboratories
• 31.8. Innovent Biologics Inc.
• 31.9. Dong-A ST Co. Ltd.
• 31.10. Alumis GmbH Co KG
• 31.11. Zai Lab Limited
• 31.12. GC Cell Corporation
• 31.13. Affibody AB
• 31.14. Nimbus Therapeutics
• 31.15. Bio-Thera Solutions

32. Global Chronic Plaque Psoriasis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Plaque Psoriasis Market

34. Recent Developments In The Chronic Plaque Psoriasis Market

35. Chronic Plaque Psoriasis Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Plaque Psoriasis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Plaque Psoriasis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Plaque Psoriasis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer